ABBVIE (ABBV) Stock: Buy, Sell, or Hold?
ABBV - ABBVIE INC.
$285.19
0.39 (0.14%)
▲
5d:
+0.63%
30d:
+7.59%
90d:
+9.96%
WAIT
LOW Confidence
Analysis Updated: Oct 22, 2026 12:00 AM ET
Earnings: Oct 30, 2026
7d
Get Alerted When ABBV Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 MIXED SIGNALS: ABBV shows conflicting indicators. Wait for confirmation before entering.
📊 MIXED SIGNALS: ABBV shows conflicting indicators. Wait for confirmation before entering.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$385.66
Based on 10.1% avg growth
INTRINSIC VALUE TODAY
$239.47
Trading above historical range
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 14.8x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: ABBV is currently trading at $285.19, which is considered extended relative to its 30-day fair value range of $261.73 to $280.02. From a valuation perspective, the stock is trading at a premium (Forward PE: 17.6) compared to its historical average (14.8). At these levels, the market is pricing in 5.9% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, ABBV is in a strong uptrend. The price is approaching resistance at $291.40. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: ABBV scores 16/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, ABBV is in a strong uptrend. The price is approaching resistance at $291.40. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: ABBV scores 16/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$261.73 -
$280.02
Company Quality Score
44/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
23.8%
Protect Your Profits
Holding ABBV? Use our AI-powered strategies to protect your downside while keeping your long-term position.
View Profit Protection PlanAll Signals
- BEARISH: Price extended above range
- BEARISH: Weak technical setup (16/100)
- BULLISH: High volume confirmation
- NEUTRAL: Near Wall St target ($282.61)
- NEUTRAL: PE elevated vs history but 5.9% growth expectation is conservative given 290% recent growth
- WARNING: Composite score 44/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$261.73 -
$280.02
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$270.38
Resistance Level
$291.40
Current Trend
Strong Uptrend
Technical data as of
Oct 22, 2026
Fundamental Context
Forward P/E (Next Year Est.)
17.58
Wall Street Target
$282.61
(-0.8%)
Revenue Growth (YoY)
10.2%
Earnings Growth (YoY)
290.4%
Profit Margin
9.8%
Valuation Premium vs History
+5.9% premium
PE vs Historical
17.6 vs 14.8
STRETCHED
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
+5.9%
(market-implied from PE analysis)
1-Year Target
$301.60
(+6%)
2-Year Target
$319.40
(+12%)
3-Year Target
$338.24
(+19%)
3-Yr Target (if PE normalizes)
(PE: 18→15)
PE COMPRESSION
$284.83
(0%)
Earnings growth offset by PE compression
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 19.9, Growth: 16.1%)
$503.53
(+77%)
Base:
(SPY PE: 17.6, Growth: 16.1%)
$445.60
(+57%)
Bear:
(PE: 14.8, Growth: 16.1%)
$375.24
(+32%)
📈
Valuation based on Current Earnings
Forward PE: 16.39 | Forward EPS (Implied): $17.37
Bull Case
$343.90
(+21%)
Analyst growth 15.0%, PE expands to 17.2
Base Case
$284.80
(0%)
Market implied 0.0%, PE stable at 16.4
Bear Case
$217.87
(-24%)
Severe decline -15.0%, PE contracts to 14.8
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
Share & Embed Analysis
Last updated: October 22, 2026 4:49 PM ET
Data refreshes hourly during market hours. Next update: 5:49 PM
Data refreshes hourly during market hours. Next update: 5:49 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is ABBV showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Featured in Portfolios
ABBV is a key holding in these high-performance investment strategies.
Top Rated Drug Manufacturers - General Stocks
Top-rated stocks in Drug Manufacturers - General by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
GILD
Gilead Sciences Inc |
STRONG BUY
28 analysts |
$160 | 43 HOLD |
|
LLY
Eli Lilly and Company |
STRONG BUY
31 analysts |
$1328 | 27 SELL |
|
BIIB
Biogen Inc |
BUY
36 analysts |
$244 | 39 SELL |
|
MRK
Merck & Company Inc |
STRONG BUY
27 analysts |
$158 | 43 HOLD |
|
JNJ
Johnson & Johnson |
BUY
23 analysts |
$279 | 59 HOLD |
Advanced ABBV Option Strategies
Professional options setups generated by AI based on today's ABBV price and gamma walls.
